On 16 June, the Global Antibiotic Research and Development Partnership (GARDP) and the National Center for Global Health and Medicine (NCGM) signed a Memorandum of … GARDP and Japan’s National Center for Global Health and Medicine signed an MOU to boost clinical research activities
The Government of Japan has granted additional funding to the Global Antibiotic Research and Development Partnership (GARDP) to support its vital work in developing new … Funding from Government of Japan will boost GARDP’s work in developing new treatments
People around the world are set to benefit from £4.5 million investment from UK Government to develop innovative treatments for drug-resistant infections which cost millions of lives every year.
Osaka (Japan), Geneva (Switzerland), Boston (USA), 15 June 2022 – Shionogi & Co., Ltd. (Shionogi) and the Global Antibiotic Research and Development Partnership (GARDP) have … Shionogi, GARDP and CHAI announce landmark license and collaboration agreements to treat bacterial infections by expanding access to cefiderocol in 135 countries
The Global Antibiotic Research and Development Partnership (GARDP) welcomes funding from the Australian Government to support its critical work in developing and delivering treatments for … GARDP welcomes funding from the Australian Government to boost its critical work to tackle drug-resistant infections
GARDP is pleased to announce funding from the Canton of Geneva to support the development of zoliflodacin, a novel antibiotic currently being assessed through a global phase 3 trial for safety and effectiveness as a treatment for gonorrhoea.
GARDP and the Department of Disease Control of the Thailand Ministry of Public Health (Thai DDC) have signed a Memorandum of Understanding (MOU) to explore opportunities to improve gonorrhea treatment in Thailand, with the intention to develop an access and stewardship strategy to ensure future antibiotics will be available as early as possible in the country.
[日本語] The Global Antibiotic Research and Development Partnership (GARDP), the Clinton Health Access Initiative (CHAI) and Shionogi & Co., Ltd today announced a Memorandum of … GARDP, CHAI and Shionogi announce MOU to increase access to antibiotic to treat antimicrobial resistant infections in low- and middle-income countries
GARDP and InfectoPharm are partnering to develop improved treatment options, using combinations of existing antibiotics, for neonatal sepsis, a leading cause of death and disability in newborns up to 28 days old. Since children of this age do not have a functioning immune system, they are more prone to developing infections and less able to overcome them.
GARDP has been granted additional funding by the Government of Japan to support the fight against drug-resistant infections, contributing to research and development into new treatments against the bacterial infections that pose the greatest threat to global health.